Jonathon Cohen

An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.

Clinical lymphoma, myeloma & leukemia · May 4, 2026

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology · May 1, 2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal · Apr 25, 2026

[Blastoïd mantle cell lymphoma, TdT-positive: Toward a more juvenile profile?].

Annales de pathologie · Apr 15, 2026

Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.

Cancer · Apr 15, 2026

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances · Feb 24, 2026

Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.

Leukemia & lymphoma · Feb 24, 2026

Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.

Current oncology (Toronto, Ont.) · May 20, 2025

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Haematologica · Jan 1, 2025

Is rituximab retro in mantle cell lymphoma?

Blood · Jul 18, 2024

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.

British journal of haematology · Jan 1, 2024